Development of STEAP-based Vaccines for the Treatment of Prostate Cancer
Annual summary 1 Nov 2004-31 Oct 2006
UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES
Pagination or Media Count:
Immunotherapy may provide an alternative treatment for cancer patients, especially when tumors over-expantigens that can be recognized by immune cells. The identification of markers and therapeutic targets that are up regulated in prostate cancer been important to design new potential treatments for prostate cancer. Among them, the recently identified six-transmembrane epithelial antigethe prostate STEAP is considered an attractive target, due to its over-expression in human prostate cancer tissues. Previously we selectprimeboost vaccination strategy DNAGFP-VRP as the best scheme to induce a specific CD8 T cell response in C57BL6 mice responsible tumor delay in complete absence of autoimmunity development but therapeutic vaccination with mSTEAP modestly controlled the growth of westablished tumors. In this report we demonstrated that CD4 T cells that produced IFNy, TNFalpha and IL-2 play the main role in tumor delay in model as demonstrated by using CD4-and CD8-deficient mice. Primeboost vaccination was unable to control tumor progression in TRAMP with prostatic intraepithelial neoplasia, In a combined treatment of androgen ablation and STEAP vaccination was successful in prostate tubearing TRAMP mice.
- Anatomy and Physiology
- Medicine and Medical Research